Compare Commvault Systems Inc (CVLT) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

Commvault Systems (CVLT) trades at $140.52, up 0.78% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with consistent earnings beats, 81% gross margins, and 32.77% ROE, though valuation metrics appear elevated with P/E at 89.35. Recent news highlights positive developments including Threat Scan integration with Google and strong Q1 2027 results with 16% subscription revenue growth.

CVLT presents growth potential with 22% ARR growth and analyst consensus target of $172.40 (23% upside), but faces risks from fiduciary investigations and high valuation multiples. The stock's technical strength and fundamental execution support bullish sentiment, though investors should monitor the ongoing legal scrutiny and margin compression from 7.64% to 5.61% net margin projection.

INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.

The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.